Skip to main content
Clinical Trials/NCT02946905
NCT02946905
Completed
Not Applicable

Neurovascular Determinants of Cognitive Function in Adults With Sickle Cell Disease

University of Pittsburgh0 sites226 target enrollmentApril 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sickle Cell Disease
Sponsor
University of Pittsburgh
Enrollment
226
Primary Endpoint
7 Tesla MRI
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Cognitive impairment is a poorly understood, serious, and emerging complication for adult patients with sickle cell disease. Because there is extensive microvascular damage from oxidative damage in sickle cell disease, the investigators hypothesize that this is also present in the cerebral microvasculature to cause cognitive impairment. The investigators plan to test this by correlating markers of inflammation and oxidative damage with cognitive performance and 7 Tesla brain MRI microvascular findings in these patients, with the long term goal of understanding the mechanisms and risk factors of cognitive impairment in sickle cell disease.

Detailed Description

The Neurovascular Determinants of Cognitive Function in Adults with Sickle Cell Disease is a study for adults 18 and older who have been diagnosed with Sickle Cell Disease (SCD). Many adult patients with SCD suffer from cognitive impairment (CI), a serious complication responsible for severe functional limitations, and whose pathogenesis, risk factors, and natural history are unknown. This research project will look at cognitive performance and 7 Tesla brain MRI findings along with markers of inflammation and oxidation to better understand the mechanism and risk factors. The investigators will complete a baseline assessment. SCD participants will be seen for follow-up at 3 and 5 years. Non-SCD participants will be seen for follow-up at 3 years. All assessments are completed at no cost and there is compensation for participation.

Registry
clinicaltrials.gov
Start Date
April 2016
End Date
March 31, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Enrico M Novelli

Assistant Professor of Medicine

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • Age 18 and above
  • Able to provide informed consent
  • For Non-SCD :
  • Between age 18 and 55
  • Able to provide informed consent
  • Are age, race, and gender matched to a Sickle Cell Disease study subject.

Exclusion Criteria

  • Age less than 18 years
  • Current pregnancy or lactation
  • Any medical condition that may result in neurocognitive or brain dysfunction that is not secondary to SCD including:
  • Diabetes mellitus
  • Coronary artery disease
  • Peripheral vascular disease
  • Other causes of cerebral vasculitis such as Systemic Lupus Erythematosus (SLE)
  • Any contraindication to MRI scanning including:
  • History of claustrophobia
  • Presence of metallic implants such as cardiac pacemaker or implantable defibrillator, surgical aneurysm clips, or any implanted device (e.g. insulin pump, drug infusion device)

Outcomes

Primary Outcomes

7 Tesla MRI

Time Frame: 5 years

Multiple conventional and novel markers of small vessel disease will be evaluated.

Secondary Outcomes

  • Inflammation(5 years)
  • Oxidative markers(5 years)

Similar Trials